How Breast Biopsy Needles Determine The Success Or Failure Of Genomics Analysis And Personalized Treatment

https://www.sirius-medical.com/knowledge/breast-biopsy-needle-techniques

In the era of precision medicine for cancer treatment, the diagnosis and treatment of breast cancer are no longer limited to cytomorphological diagnosis under pathological sections. Concepts such as driver gene mutations, immune microenvironment markers, and tumor heterogeneity have become the core basis for formulating targeted therapy and immunotherapy plans. And the starting point for all this is the quality of the tissue sample obtained by that small breast biopsy needle.

Sample Quality: The First Checkpoint Determining the Success of Molecular Testing

Traditional Fine-Needle Aspiration (FNA) can only obtain cell suspensions. Although usable for preliminary cytological diagnosis, it is far from sufficient for precision testing requiring adequate DNA and RNA extraction for Next-Generation Sequencing (NGS). Therefore, Core Needle Biopsy (CNB) and Vacuum-Assisted Biopsy (VAB) have become the standard configuration. They can obtain tissue strips with a diameter of 1-3mm and a length of 10-30mm, weighing typically between 5-50mg. This seemingly insignificant tissue is the key to unlocking the tumor's genetic map.

The Relationship Between Biopsy Needle Design and Molecular Integrity

The mechanical design of the biopsy needle directly affects the integrity of the tissue sample. For example:

• Cutting Mechanism:​ Sharp blades with a negative angle can cleanly sever tissue, reducing squeezing and pulling. Conversely, blunt blades or excessive shear force can cause tissue fragmentation, destroying cell membrane integrity and leading to RNA degradation.
• Vacuum Assistance:​ VAB needles gently suck tissue into the side notch via vacuum, avoiding the violent impact on tissue at the moment of "firing" typical of traditional spring-loaded needles. Studies have shown that samples obtained by VAB have significantly higher RNA Integrity Number (RIN) values than those from conventional CNB, making them more suitable for single-cell RNA sequencing.
• Needle Gauge and Bleeding:​ Larger gauge needles (such as 8G, 10G) can obtain more tissue but also increase the risk of hematoma. Nucleases in the blood will rapidly degrade free nucleic acids. Therefore, delicate operating skills and hemostatic designs (such as tract sealing materials) are crucial for protecting the sample.

From Tissue to Data: The "Chain Reaction" of Biopsy Needles

A qualified biopsy needle influences the entire precision medicine chain:

• HER2 Testing:​ Requires intact cell membrane structures. Severely crushed samples can lead to false-negative results, missing the opportunity for trastuzumab treatment.
• PD-L1 Expression:​ Requires immunohistochemical staining on intact tissue sections. Fragmented samples cannot assess the proportion of tumor cells or the spatial distribution of positive staining.
• Tumor Mutational Burden (TMB):​ Requires sufficient DNA for whole-exome sequencing. Insufficient sample volume or fragmented DNA can lead to sequencing failure or biased results.
• Circulating Tumor DNA (ctDNA) Control:​ Tissue samples obtained from biopsy are the "gold standard" for interpreting ctDNA mutations in the blood. Incorrect biopsy samples will mislead the interpretation of liquid biopsy results.

Future Outlook: The Biopsy Needle as a "Sensor"

Next-generation biopsy needles will not just be sampling tools, but "intelligent sensors" integrating in-situ molecular analysis capabilities. For example, a mass spectrometry biopsy needle called the "Mass Spec Pen" can instantly analyze metabolites released by tissue upon puncture to determine malignancy in real-time. Another photoacoustic imaging biopsy needle uses laser-induced tumor-specific fluorescence to guide doctors to sample from the most "active" area. These technologies will make the biopsy process itself a rapid molecular diagnosis, greatly shortening the time window from sampling to obtaining genetic reports.

Conclusion:

In the grand narrative of precision medicine, the breast biopsy needle plays the role of the "first domino." Every cut, every suction, writes the script for subsequent treatment plans. For clinicians, understanding and choosing the right biopsy needle is not just completing a procedure, but fighting for a precise diagnostic opportunity that could change the patient's fate. Investing in high-quality biopsy equipment is investing in the future of precision medicine.